Posts under the hematologic malignancies category associated.
By: Dr. Kanak Parmar On October 24, 2023 the U.S. Food and Drug Administration approved ivosidenib for adult patients with…
By Akshat Jain MD, MPH Hematology Oncology and Cellular Therapy Faculty Department of Pediatrics & Clinical Medicine Loma Linda University…
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Hodgkin’s lymphoma (HL) has had an exciting and…
Imetelstat in low-risk MDS for transfusion independence By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center …
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Low-risk MDS had many exciting updates, starting with…
By Dr. Chepsy Philip Believer's Church Medical College Hospital Myeloproliferative - Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the…
By Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic In the…
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Combination chemoimmunotherapy with the chemo regimen R-CHOP (Rituximab,…
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center The Zuma 7 trial is a randomized, open-label multicenter…
By Dr. Richa Parikh Karmanos Cancer Institute & Dr. Harsh Parmar Hackensack Meridian Health A multicenter retrospective study, which…